Why the investor craze for Ozempic and rival weight-loss drugs may resume next year
Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...
The Weight-Loss Drug Market Is Heading for a Reckoning This Week
The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...
I poisoned myself with a weight-loss jab and thought I was dying. Six months later, I'm still battling a bizarre side-effect that's destroyed my willpower and made me wi…
It's been six months since I accidentally poisoned myself with a weight-loss jab I shouldn't have taken. But while the memory ...
Novo Nordisk invests $1.2 billion in new rare disease drugs plant in Denmark
STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in ...
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...
The Peninsula5h
Weight-loss drugmaker Novo Nordisk invests $1.2 bn in new factory in Denmark
Copenhagen: Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight loss treatments Ozempic and Wegovy, said Monday it was investing ...
Novo Nordisk invests $1.2 bln in new rare disease drugs plant in Denmark
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...
The Local5h
Novo Nordisk announces billion-dollar investment in new Danish factory
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...
People Aren't Using Ozempic 'Responsibly', Says Doctor
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
devdiscourse10h
Novo Holdings Acquires Catalent: A Deal to Boost Weight-Loss Drug Production
Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...
2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious
On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...